Stifel Financial
NAVB

Stifel Financial’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Stifel Financial’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,898
Closed -$116K – 2558
2016
Q2 		$116K Buy
+10,898
New +$214K ﹤0.01% 2362

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Stifel Financial's NAVB Position: Q3 2016 in Review

Stifel Financial sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2016, closing a stake of 10,898 shares — an estimated $116K sold.

Stifel Financial first reported a position in NAVB in Q2 2016 and held it in 1 quarter. The position peaked at $116K in Q2 2016. 55 funds tracked by Wall St. Rank hold NAVB as of Q3 2016.

  • Stifel Financial reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
  • Stifel Financial sold 10,898 Navidea Biopharmaceuticals Inc. shares in Q3 2016, an estimated $116K.
  • Stifel Financial first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and held it in 1 quarter.
  • Stifel Financial's Navidea Biopharmaceuticals Inc. position peaked at $116K in Q2 2016.
  • 55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2016.

Based on Stifel Financial's 13F filing for Q3 2016, filed 15 Nov 2016.